Maintaining mood stability in bipolar disorder: a clinical perspective on pharmacotherapy

Gin S Malhi,1,2 Claire McAulay,1,2 Pritha Das,1,2 Kristina Fritz1,2

1Discipline of Psychiatry, Sydney Medical School, University of Sydney, St Leonards, New South Wales, Australia; 2Department of Psychiatry, CADE Clinic, Royal North Shore Hospital, St Leonards, New South Wales, Australia

Correspondence to Professor Gin S Malhi, Discipline of Psychiatry, Sydney Medical School, University of Sydney, St Leonards, NSW 2066, Australia; gin.malhi@sydney.edu.au

▸ Additional material is published online only. To view please visit the journal online (http://dx.doi.org/10.1136/eb-2014-101948).

INTRODUCTION

Bipolar disorder is defined by its poles, elevated mood or irritability characterises mania, and marked low mood and lack of energy typifies depression. Treatment of these acute states is necessary for the patient’s well-being but the major management challenge lies in reducing the frequency and severity of relapses and recurrences, and maintaining healthy mood. Typically, patients with bipolar disorder experience a recurrence every 17–30 months and have multiple episodes over the course of the illness.1 Successful management of this chronic, recurrent illness ultimately depends on maintaining long-term mood stability and preventing further episodes of depression and mania. It is therefore, all the more remarkable that maintenance therapies have received sparse attention; this is partly because longitudinal research is difficult to design and conduct. Therefore, clinicians often have to draw on experience regarding the long-term use of medications. This paper outlines the options for long-term pharmacotherapy of bipolar disorder and addresses common clinical questions regarding administration, drawing on a synthesis of current evidence for maintenance agents.

METHODS

To identify relevant evidence for the long-term pharmacological management of bipolar disorder electronic database searches were conducted using Summon (the University of Sydney’s cross-search engine), OvidSP (including PubMed and PsycINFO) and Cochrane reviews. Searches were limited to the past 7 years. In addition existing systematic reviews were carefully scrutinised and their bibliographies drawn on to identify additional studies of note which were appraised alongside recent clinical trials. This review primarily included studies that were randomised, placebo-controlled, blinded, non-enriched and of sufficient duration to be regarded as maintenance therapy. Studies that did not meet all these principal requirements, such as those with external validity in non-randomised settings, were also reviewed cautiously and their findings were considered with limitations. Their impact in determining treatment decisions was moderated accordingly. The need to institute this process reflects the paucity of robust evidence.

Long-term treatment

The key goal of long-term treatment is the prevention of further mood episodes, but in practice 100% prevention is exceptional.2 Almost half of all treated patients experience a recurrence within 2 years and 70–90% within 5 years.3 Therefore, the aims of long-term treatment have to be broader and include a reduction in inter-episode symptoms along with a reduction in the frequency and severity of episodes.2 Long-term treatment of bipolar disorder consists of a continuation stage and subsequent maintenance stage, as shown in figure 1. The continuation stage of treatment begins immediately after the remission of acute symptoms. Generally, medication doses tend to be higher during the acute phase of the illness and thus, should be tapered down during continuation treatment. During this time, frequent follow-up and close supervision is necessary as patients remain vulnerable to relapse. Continuation treatment aims to sustain clinical improvement and prevent relapse and patient adherence is critical during this stage.4 Maintenance treatment starts once reasonable mood stability has been achieved following continuation treatment, which usually comprises 3–6 months of continued mood stability. Figure 1 shows successive progression through these treatment stages. The long-term goal of maintenance treatment is to reach optimum (or premorbid) functioning, which includes maintaining optimal mood stability (see box 1) and the prevention of new mood episodes (recurrence).

In practice: initiation

Following diagnosis, a key issue in early management is the patient’s acceptance of the chronic nature of bipolar disorder and the need for regular lifelong follow-up. Many patients first experience mania as adolescents or young adults5 and are daunted by the diagnosis, but frequent recurrences make the necessity of continual management evident. The polarity of bipolar disorder usefully informs long-term pharmacotherapy, and while depression is more common (because depressive episodes tend to last longer), some patients are mania-dominant (especially early in the illness) or are equally likely to experience both phases. This is important because some agents have greater efficacy...
for preventing mania or depression. Knowledge of the patient’s illness pattern informs long-term goals, as debilitating depression may be a core treatment goal for some, whereas manic symptoms or lack of mood stability may cause greater functional impairment for others. Note, the pattern of polarity often changes over time and therefore the most recent episode is an important factor in treatment decisions. Primary and secondary continuation treatment options are illustrated in figure 2A. Drugs that have shown past efficacy should be engaged before novel agents.

**Monitoring and adherence**
Following approximately 3–6 months of continuation treatment, patients enter the maintenance stage, where most or all symptoms have resolved and the focus is the prevention and promotion of healthy mood. Medications should be reassessed and any symptoms or side-effects monitored regularly; this may inform the decision to either taper, increase or switch agents; further, manage associated health concerns, such as metabolic changes (see figure 2B). In bipolar disorder, adherence to long-term treatment with medications is not achieved easily. Dissatisfaction with the efficacy of treatment, coupled with the additional burden of side effects, financial cost of regular follow-up and the desire to put the illness and its associated memories out of mind, all contribute to poor compliance and the likelihood of cessation. Indeed, almost all patients with bipolar disorder will have a period of poor compliance at some point in the course of their illness, but it is best to try and decrease these periods of non-adherence.

The medication regimen may need to be modified in instances where reduced adherence is caused by poor tolerability, or where severe side effects, such as renal failure or metabolic syndrome, pose serious health risks. It is important to identify subsyndromal symptoms, as these can significantly limit functioning, and regularly review the effectiveness of ongoing treatment, so as to anticipate prodromal symptoms and future recurrences. Strategies of switching or stopping maintenance medication in order to address poor effectiveness or tolerance are outlined in figure 2B.

**Pharmacotherapy treatments**
Maintenance treatment research is relatively nascent, and therefore, there is a dearth of knowledge in comparison to the acute treatment of bipolar disorder. Furthermore, studies that have explored long-term treatment have many shortcomings. For example, they do not have sufficient long-term follow-up, they often fail to differentiate between remission versus relapse, and/or they do not clearly define and separate continuation and maintenance treatment. They often use ‘enriched’ patient samples (ie, assessing agents with known efficacy in specific patients), limiting generalisability of the findings. Furthermore, patients are usually admitted into studies while recovering from manic and mixed episodes, rather than depression, even though depression is the predominant phase of the illness and may confer greater functional impairment in the long term. These limitations inherently favour fast-acting agents such as second-generation antipsychotics, which primarily reduce agitation and assist sleep rather than stabilise mood and therefore, only offer benefit during the continuation stage. Thus, many second-generation antipsychotics (SGAs) are recommended as maintenance agents in treatment guidelines, which is problematic given the significant risks of metabolic and medical complications long term. Recent reviews have provided a small basis for specific maintenance agents. However, in addition to research design flaws, it must be noted that many agents have simply insufficient evidence and await the outcomes of further research. Until more suitable long-term studies are conducted, clinicians must exercise their best judgement and employ trial and error to determine the best long-term agents for individual patients, taking care to consider their polarity index. This served to offer due consideration to promising new research on maintenance. Figure 3 summarises the utility of some common maintenance agents.

**Mood stabilisers**
Lithium, the original mood stabiliser, remains the gold standard in bipolar management (for acute and long term), especially for manic-dominant patients, and because of its prophylactic and antisuicidal properties. Approximately one-third of lithium-treated patients experience no further major episodes for up to 10 years, but this is not an excuse for complacency because abrupt cessation is quite likely to prompt recurrence. Monotherapy is ideal but often not adequate, and lithium can often be successfully combined with adjunctive lamotrigine or quetiapine.

**Anticonvulsants**
While valproate has reported empirical efficacy, only a few clinical trials support its long-term use. Interestingly, a recent review suggested that valproate may have superior tolerability compared to lithium for some patients. However, the BALANCE study, which had utilised a 2-year follow-up period, found that lithium was superior to valproate and that the combination of the two medications was better than either alone in preventing depressive recurrences. Lamotrigine is most effective as a bipolar maintenance agent with patients who experience depressive-dominant bipolar disorder. It has shown efficacy as monotherapy and as an adjunct to lithium in reducing the risk of recurrence, particularly of depression. Carbamazepine is another option that has shown some efficacy predominantly as an adjunct, but due to its side effect burden, should be considered only after more readily-tolerated agents fail to yield benefits.

**Second Generation Antipsychotics**
Newer Second Generation Antipsychotics (SGAs) are increasingly being proposed as viable long-term treatments for bipolar disorder; however, substantive research only exists for two agents thus far—quetiapine and olanzapine. Quetiapine is a front-line monotherapy option and may suit patients with mixed features, rapid cycling, marked agitation and sleep deficits. It has been shown to be equivalent to lithium in prevention of recurrences and demonstrates efficacy in either polarity, but only in short-term studies that lack an active
Olanzapine is also commonly used as monotherapy, typically in manic-dominant patients. It is arguably comparable to valproate for preventing mania but has not shown efficacy in preventing depression. Agents that show promise are being investigated; for example, the ARIQUELI study, currently nearing completion, examines whether aripiprazole (an SGA) confers benefit in preventing bipolar

Figure 2  (A) Decision-making diagram for continuation treatment in bipolar disorder (QoL, quality of life). (B) Decision-making diagram for maintenance treatment in bipolar disorder.
disorder relapse and recurrence when administered as an adjunct to quetiapine or lithium. It has previously been shown some prophylactic efficacy against mania but not depression and as adjunct to lithium or valproate. Risperidone, a long-acting injectable, has been shown to improve outcomes and reduce the risk of manic recurrence. Clozapine is rarely recommended given its high risk of side effects but may suit treatment-resistant patients who are able to engage with regular monitoring.

**Antidepressants**

Antidepressants are no longer recommended as monotherapy, partly due to questionable efficacy and the elevated risk of switching to mania with these agents. However, in treatment-resistant, depressive-dominant patients, a selective serotonin reuptake inhibitor in combination with a mood stabiliser such as lithium may be suitable after exhausting alternative combinations; this requires a strict consideration of inherent risks.

**Side effects**

Side effects of bipolar disorder agents are common during acute and continuation treatment, but can be alleviated to some extent by tapering in the maintenance stage. However, some distressing symptoms often persist. Some of the side effects are serious and only become apparent long-term. Therefore, clinicians must be cognisant of these tolerability issues and also need to be aware of the needs of different patient groups. For instance, women of childbearing age are susceptible to teratogenic side effects and treatment needs to be reviewed when planning pregnancy, while older patients may be at greater risk for acute or chronic toxicity and renal dysfunction.

Naturally, different medications require separate schedules for monitoring side-effects or toxicity, and given that polypharmacy is common, patients may require quite frequent investigations and follow-up. Table 2 summarises recommended schedules for review.

**Patient diversity: disease and individual factors relevant to pharmacotherapy**

Few patients with bipolar disorder experience only a single episode of the illness during their lifetime and therefore, maintenance treatment is

---

**Table 1** Optimal maintenance agents in bipolar disorder

<table>
<thead>
<tr>
<th>Maintenance agent</th>
<th>CBR*</th>
<th>EBR†</th>
<th>Utility</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mood stabiliser</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lithium</td>
<td>✓✓✓</td>
<td>Level I</td>
<td>Classic frontline option for bipolar, especially mania-dominant. Commonly used as adjunct with atypical antipsychotics. Requires close monitoring to maintain within therapeutic preventative levels. High risk of recurrence on abrupt cessation.</td>
</tr>
<tr>
<td>Anticonvulsants</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Carbamazepine</td>
<td>✓✓</td>
<td>—</td>
<td>Less effective than lithium; may confer greater benefit in combination with lithium than either alone. Not a first-choice choice. High potential side-effect burden.</td>
</tr>
<tr>
<td>Lamotrigine</td>
<td>✓✓</td>
<td>Level III</td>
<td>More effective for preventing depressive recurrence. Commonly used in combination with an antimanic prophylactic agent but may be suitable as monotherapy for depressive-dominant patients. May be appropriate for non-classic cases with mixed features or rapid cycling.</td>
</tr>
<tr>
<td>Valproate</td>
<td>✓✓</td>
<td>Level III</td>
<td>Evidence not yet robust but commonly used for maintenance. Recent review found some limited evidence of maintenance efficacy, as adjunct. Evidence suggests better adherence than for lithium. Strongly contraindicated in pregnancy.</td>
</tr>
</tbody>
</table>

**Second-generation antipsychotics**

<table>
<thead>
<tr>
<th>Antipsychotic</th>
<th>Level III as adjunct</th>
<th>Utility</th>
</tr>
</thead>
<tbody>
<tr>
<td>Risperidone-LAI</td>
<td>✓</td>
<td>Suitable for rapid cyclers in short term. Evidence of long-term maintenance efficacy as adjunct.</td>
</tr>
<tr>
<td>Ziprasidone</td>
<td>✓</td>
<td>Some evidence suggesting suitable as adjunct for long-term mania prophylaxis.</td>
</tr>
</tbody>
</table>

*Consensus-based research derived from working group preparing Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guideline: Mood Disorders for ANZJP (Malti et al, 2014; under consideration from ANZJP). Checks indicate strength of available evidence for use — indicates strong, 2 moderate or 1 limited.
†Evidence-based research using NHMRC levels of evidence. I, systematic review of level II studies; II, randomised controlled trial; III, other study designs using controls; IV, case series with post-test or pretest/post-test outcomes.
Adjunctive psychotherapy and novel adjunctive agents

Bipolar disorder benefits from a multifaceted approach that targets lifestyle factors and psychological strategies to promote long-term well-being. This may include structured psychological therapy, such as interpersonal rhythm therapy, family-focussed therapy, cognitive–behavioural therapy or acceptance and commitment therapy. These have been shown to sustain health and prevent relapse, in conjunction with pharmacotherapy. Substance abuse is highly prevalent in this population and should be recognised as a potential trigger, alongside signs of a shift in mood and/or coping. Psychoeducation is therefore important for managing medication and promoting adherence, also managing the disease long term. Regular 12-month follow-up appointments with the clinician can serve to provide interepisode support as well as screening for any noteworthy symptoms or disruption to functioning, from the disease or medication regime.

In addition to healthy lifestyle, there are recent novel directions in adjunctive agents for bipolar disorder. For example, N-acetyl cysteine, a mitochondrial agent, has been shown to improve depressive symptoms by alleviating oxidative stress in the brain. This may improve long-term cognitive, psychosocial and functional impairment. ω-3 Fatty acids may also help with the cognitive burden of bipolar.

CONCLUSION

Maintenance treatment and long-term prophylaxis are necessarily complicated and require sophisticated management. Pharmacotherapy is one component of a broader set of strategies. To be successful it requires an indepth understanding of the illness, the unique requirements of the patient and a robust therapeutic alliance. Long-term mood stability can be achieved but goals need to be realistic and inevitable for most. From a management perspective, the need for pharmacotherapy is indisputable but patient preference is important and the nature and trajectory of the illness also play a significant role.

Classic bipolar I disorder is typically less treatment-resistant, partly because it does not usually encompass challenging features such as rapid cycling or mixed states. In contrast, bipolar II disorder may involve a complex pattern of illness, often including ‘milder’ or less acutely disruptive features that nonetheless can exert a significant functional burden. Similarly, the management of subsyndromal symptoms is probably more important than previously thought and medications may be appropriate alongside psychological therapy. Complex presentations of bipolar disorder are increasingly recognised and involve symptoms such as mixed states, agitation and mood lability, which perhaps respond better to carbamazepine or fast-acting antipsychotic agents given the significance of early response.

If adherence becomes an issue then long-acting injectable agents reduce treatment burden and the risk of relapse. For a small number of patients, psychological approaches may serve as sufficient for prophylaxis and monitoring between more acute phases, especially after weighing up the potential benefits versus costs of medication. While not ideal, this may be preferable to irreparably damaging the therapeutic alliance by disregarding patient preferences. Box 2 seeks to address some common clinical questions about maintenance treatment.

### Table 2  Assessment frequency for reviewing health effects of bipolar medications

<table>
<thead>
<tr>
<th>Medication</th>
<th>Investigations/examinations</th>
<th>Suggested assessment timetable during treatment (months)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Initiation</td>
<td>6</td>
</tr>
<tr>
<td>Carbamazepine</td>
<td>Full blood count</td>
<td>✓</td>
</tr>
<tr>
<td>L lamotrigine</td>
<td>Full blood count</td>
<td>✓</td>
</tr>
<tr>
<td>Lithium</td>
<td>Renal (urea, creatinine, electrolytes)</td>
<td>✓</td>
</tr>
<tr>
<td>Olanzapine</td>
<td>Physical</td>
<td>✓</td>
</tr>
<tr>
<td>Quetiapine</td>
<td>Physical</td>
<td>✓</td>
</tr>
<tr>
<td>Valproate</td>
<td>Full blood count</td>
<td>✓</td>
</tr>
</tbody>
</table>

TSH, thyroid-stimulating hormone; BMI, body mass index.

Derived from Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guideline: Mood Disorders. (Malhi et al, 2014; under consideration from ANZJP).
management needs to include monitoring and modifications of medication in order for these to be fulfilled.

Competing interests None.

doi:10.1136/eb-2014-101948

REFERENCES
